Preclinical efficacy and safety analysis of gamma-irradiated inactivated SARS-CoV-2 vaccine candidates
Abstract COVID-19 outbreak caused by SARS-CoV-2 created an unprecedented health crisis since there is no vaccine for this novel virus. Therefore, SARS-CoV-2 vaccines have become crucial for reducing morbidity and mortality. In this study, in vitro and in vivo safety and efficacy analyzes of lyophili...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/46a25aaed32541e28966db05d0693f25 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:46a25aaed32541e28966db05d0693f25 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:46a25aaed32541e28966db05d0693f252021-12-02T13:34:51ZPreclinical efficacy and safety analysis of gamma-irradiated inactivated SARS-CoV-2 vaccine candidates10.1038/s41598-021-83930-62045-2322https://doaj.org/article/46a25aaed32541e28966db05d0693f252021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-83930-6https://doaj.org/toc/2045-2322Abstract COVID-19 outbreak caused by SARS-CoV-2 created an unprecedented health crisis since there is no vaccine for this novel virus. Therefore, SARS-CoV-2 vaccines have become crucial for reducing morbidity and mortality. In this study, in vitro and in vivo safety and efficacy analyzes of lyophilized vaccine candidates inactivated by gamma-irradiation were performed. The candidate vaccines in this study were OZG-3861 version 1 (V1), an inactivated SARS-CoV-2 virus vaccine, and SK-01 version 1 (V1), a GM-CSF adjuvant added vaccine. The candidate vaccines were applied intradermally to BALB/c mice to assess toxicity and immunogenicity. Preliminary results in vaccinated mice are reported in this study. Especially, the vaccine models containing GM-CSF caused significant antibody production with neutralization capacity in absence of the antibody-dependent enhancement feature, when considered in terms of T and B cell responses. Another important finding was that the presence of adjuvant was more important in T cell in comparison with B cell response. Vaccinated mice showed T cell response upon restimulation with whole inactivated SARS-CoV-2 or peptide pool. This study shows that the vaccines are effective and leads us to start the challenge test to investigate the gamma-irradiated inactivated vaccine candidates for infective SARS-CoV-2 virus in humanized ACE2 + mice.Gozde Sir KarakusCihan TastanDerya Dilek KancagiBulut YurtseverGamze TumentemurSevda DemirRaife Dilek TuranSelen AbanuzDidem CakirsoyUtku SeyisSamed OzerOmer ElibolMuhammer ElekGurcan ErtopSerap ArbakMerve Acikel ElmasCansu HemsinliogluAyse Sesin KocagozOzden Hatirnaz NgSezer AkyoneyIlayda SahinUgur OzbekDilek TelciFikrettin SahinKoray YalcinSiret RatipErcument OvaliNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-19 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Gozde Sir Karakus Cihan Tastan Derya Dilek Kancagi Bulut Yurtsever Gamze Tumentemur Sevda Demir Raife Dilek Turan Selen Abanuz Didem Cakirsoy Utku Seyis Samed Ozer Omer Elibol Muhammer Elek Gurcan Ertop Serap Arbak Merve Acikel Elmas Cansu Hemsinlioglu Ayse Sesin Kocagoz Ozden Hatirnaz Ng Sezer Akyoney Ilayda Sahin Ugur Ozbek Dilek Telci Fikrettin Sahin Koray Yalcin Siret Ratip Ercument Ovali Preclinical efficacy and safety analysis of gamma-irradiated inactivated SARS-CoV-2 vaccine candidates |
| description |
Abstract COVID-19 outbreak caused by SARS-CoV-2 created an unprecedented health crisis since there is no vaccine for this novel virus. Therefore, SARS-CoV-2 vaccines have become crucial for reducing morbidity and mortality. In this study, in vitro and in vivo safety and efficacy analyzes of lyophilized vaccine candidates inactivated by gamma-irradiation were performed. The candidate vaccines in this study were OZG-3861 version 1 (V1), an inactivated SARS-CoV-2 virus vaccine, and SK-01 version 1 (V1), a GM-CSF adjuvant added vaccine. The candidate vaccines were applied intradermally to BALB/c mice to assess toxicity and immunogenicity. Preliminary results in vaccinated mice are reported in this study. Especially, the vaccine models containing GM-CSF caused significant antibody production with neutralization capacity in absence of the antibody-dependent enhancement feature, when considered in terms of T and B cell responses. Another important finding was that the presence of adjuvant was more important in T cell in comparison with B cell response. Vaccinated mice showed T cell response upon restimulation with whole inactivated SARS-CoV-2 or peptide pool. This study shows that the vaccines are effective and leads us to start the challenge test to investigate the gamma-irradiated inactivated vaccine candidates for infective SARS-CoV-2 virus in humanized ACE2 + mice. |
| format |
article |
| author |
Gozde Sir Karakus Cihan Tastan Derya Dilek Kancagi Bulut Yurtsever Gamze Tumentemur Sevda Demir Raife Dilek Turan Selen Abanuz Didem Cakirsoy Utku Seyis Samed Ozer Omer Elibol Muhammer Elek Gurcan Ertop Serap Arbak Merve Acikel Elmas Cansu Hemsinlioglu Ayse Sesin Kocagoz Ozden Hatirnaz Ng Sezer Akyoney Ilayda Sahin Ugur Ozbek Dilek Telci Fikrettin Sahin Koray Yalcin Siret Ratip Ercument Ovali |
| author_facet |
Gozde Sir Karakus Cihan Tastan Derya Dilek Kancagi Bulut Yurtsever Gamze Tumentemur Sevda Demir Raife Dilek Turan Selen Abanuz Didem Cakirsoy Utku Seyis Samed Ozer Omer Elibol Muhammer Elek Gurcan Ertop Serap Arbak Merve Acikel Elmas Cansu Hemsinlioglu Ayse Sesin Kocagoz Ozden Hatirnaz Ng Sezer Akyoney Ilayda Sahin Ugur Ozbek Dilek Telci Fikrettin Sahin Koray Yalcin Siret Ratip Ercument Ovali |
| author_sort |
Gozde Sir Karakus |
| title |
Preclinical efficacy and safety analysis of gamma-irradiated inactivated SARS-CoV-2 vaccine candidates |
| title_short |
Preclinical efficacy and safety analysis of gamma-irradiated inactivated SARS-CoV-2 vaccine candidates |
| title_full |
Preclinical efficacy and safety analysis of gamma-irradiated inactivated SARS-CoV-2 vaccine candidates |
| title_fullStr |
Preclinical efficacy and safety analysis of gamma-irradiated inactivated SARS-CoV-2 vaccine candidates |
| title_full_unstemmed |
Preclinical efficacy and safety analysis of gamma-irradiated inactivated SARS-CoV-2 vaccine candidates |
| title_sort |
preclinical efficacy and safety analysis of gamma-irradiated inactivated sars-cov-2 vaccine candidates |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/46a25aaed32541e28966db05d0693f25 |
| work_keys_str_mv |
AT gozdesirkarakus preclinicalefficacyandsafetyanalysisofgammairradiatedinactivatedsarscov2vaccinecandidates AT cihantastan preclinicalefficacyandsafetyanalysisofgammairradiatedinactivatedsarscov2vaccinecandidates AT deryadilekkancagi preclinicalefficacyandsafetyanalysisofgammairradiatedinactivatedsarscov2vaccinecandidates AT bulutyurtsever preclinicalefficacyandsafetyanalysisofgammairradiatedinactivatedsarscov2vaccinecandidates AT gamzetumentemur preclinicalefficacyandsafetyanalysisofgammairradiatedinactivatedsarscov2vaccinecandidates AT sevdademir preclinicalefficacyandsafetyanalysisofgammairradiatedinactivatedsarscov2vaccinecandidates AT raifedilekturan preclinicalefficacyandsafetyanalysisofgammairradiatedinactivatedsarscov2vaccinecandidates AT selenabanuz preclinicalefficacyandsafetyanalysisofgammairradiatedinactivatedsarscov2vaccinecandidates AT didemcakirsoy preclinicalefficacyandsafetyanalysisofgammairradiatedinactivatedsarscov2vaccinecandidates AT utkuseyis preclinicalefficacyandsafetyanalysisofgammairradiatedinactivatedsarscov2vaccinecandidates AT samedozer preclinicalefficacyandsafetyanalysisofgammairradiatedinactivatedsarscov2vaccinecandidates AT omerelibol preclinicalefficacyandsafetyanalysisofgammairradiatedinactivatedsarscov2vaccinecandidates AT muhammerelek preclinicalefficacyandsafetyanalysisofgammairradiatedinactivatedsarscov2vaccinecandidates AT gurcanertop preclinicalefficacyandsafetyanalysisofgammairradiatedinactivatedsarscov2vaccinecandidates AT seraparbak preclinicalefficacyandsafetyanalysisofgammairradiatedinactivatedsarscov2vaccinecandidates AT merveacikelelmas preclinicalefficacyandsafetyanalysisofgammairradiatedinactivatedsarscov2vaccinecandidates AT cansuhemsinlioglu preclinicalefficacyandsafetyanalysisofgammairradiatedinactivatedsarscov2vaccinecandidates AT aysesesinkocagoz preclinicalefficacyandsafetyanalysisofgammairradiatedinactivatedsarscov2vaccinecandidates AT ozdenhatirnazng preclinicalefficacyandsafetyanalysisofgammairradiatedinactivatedsarscov2vaccinecandidates AT sezerakyoney preclinicalefficacyandsafetyanalysisofgammairradiatedinactivatedsarscov2vaccinecandidates AT ilaydasahin preclinicalefficacyandsafetyanalysisofgammairradiatedinactivatedsarscov2vaccinecandidates AT ugurozbek preclinicalefficacyandsafetyanalysisofgammairradiatedinactivatedsarscov2vaccinecandidates AT dilektelci preclinicalefficacyandsafetyanalysisofgammairradiatedinactivatedsarscov2vaccinecandidates AT fikrettinsahin preclinicalefficacyandsafetyanalysisofgammairradiatedinactivatedsarscov2vaccinecandidates AT korayyalcin preclinicalefficacyandsafetyanalysisofgammairradiatedinactivatedsarscov2vaccinecandidates AT siretratip preclinicalefficacyandsafetyanalysisofgammairradiatedinactivatedsarscov2vaccinecandidates AT ercumentovali preclinicalefficacyandsafetyanalysisofgammairradiatedinactivatedsarscov2vaccinecandidates |
| _version_ |
1718392731563196416 |